Valisure’s Zantac tests: what do they show?

Valisure raised concerns in 2019. FDA questioned a heated test, then later asked makers to withdraw older ranitidine. Those records do not prove what caused your cancer.

What did Valisure ask FDA to do?

It asked FDA to remove the drug from sale in September 2019. That was a request. It was not an agency order or a court ruling.

Valisure reported its own tests and proposed explanations for impurity formation. Keep the request’s claims attributed to its authors rather than treating the requested action as already granted on that date.

Was this a study of cancer in patients?

No. It reported lab tests and arguments. It did not follow a group of patients to find who developed cancer from the drug.

Its tables concern products and lab models. Citing other research does not make those patients part of the lab’s own test data. A lab result cannot diagnose an individual user.

What concern did FDA raise about heated testing?

FDA said a heated test can create impurity from ranitidine. A lower-heat method found lower levels. That does not mean every product was clean.

That criticism concerns the test conditions. It does not show that all products lacked the impurity or invalidate every separate concern raised by the laboratory. Read the agency method update with the dated request.

Did FDA’s own testing settle every body-model claim?

No. FDA found no added impurity in its stomach-fluid model. That model does not reflect every person’s use or health.

Its selected product tests also gave varying results. Keep sample chemistry separate from cancer outcomes and from a person’s actual dose. Neither kind of laboratory result is a private medical assessment.

Why did FDA still request withdrawal in 2020?

The impurity could increase as the older drug aged or got warm. FDA asked makers to remove those products in April 2020.

That later action rests on a product-safety assessment. It does not establish that every older dose caused cancer. The 2023 comparative user study also has exposure and follow-up limits.

How should I read this alongside the newer approval?

FDA approved new tablets in November 2025 after work to address impurity formation. The later decision concerns the new formula.

An old laboratory request is not a current instruction to stop or switch medicines. Ask your clinician about the product you actually have and follow its storage directions.